Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
600 participants
INTERVENTIONAL
2006-01-31
2007-05-14
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Patients included in the study must have symptoms of OAB (frequency of at least 8 per day and Urgency of at least 1 episode per day confirmed by bladder diary).
Patients are not eligible to enroll in the study if they have/had significant hepatic or renal disease, history of radiation treatment.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effect Of Detrol LA With Behavioral Intervention In Overactive Bladder Subjects Dissatisfied With Recent OAB Medication.
NCT00230789
Effect of Detrol LA on Overactive Bladder Symptoms, Sexual Quality of Life and Sexual Function in Women
NCT00143481
Study to Determine The Effectiveness Of Detrusitol In Patients Diagnosed With OAB
NCT00143377
Efficacy and Tolerability of DITROPAN XL (Oxybutynin Chloride) Versus DETROL LA (Tolterodine Tartrate) in Treatment of Overactive Bladder
NCT00293839
A Study to Evaluate the Efficacy of Tolterodine on Specific Symptoms in Adult Patients With Overactive Bladder.
NCT00645281
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Detrol LA
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
40 Years
MALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
INDUSTRY
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pfizer CT.gov Call Center
Role: STUDY_DIRECTOR
Pfizer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Pfizer Investigational Site
Anaheim, California, United States
Pfizer Investigational Site
La Mesa, California, United States
Pfizer Investigational Site
Aurora, Colorado, United States
Pfizer Investigational Site
Iowa City, Iowa, United States
Pfizer Investigational Site
Shreveport, Louisiana, United States
Pfizer Investigational Site
Watertown, Massachusetts, United States
Pfizer Investigational Site
Woodlane, New Jersey, United States
Pfizer Investigational Site
New York, New York, United States
Pfizer Investigational Site
Cincinnati, Ohio, United States
Pfizer Investigational Site
State College, Pennsylvania, United States
Pfizer Investigational Site
Houston, Texas, United States
Pfizer Investigational Site
Calgary, Alberta, Canada
Pfizer Investigational Site
Surrey, British Columbia, Canada
Pfizer Investigational Site
Victoria, British Columbia, Canada
Pfizer Investigational Site
Kingston, Ontario, Canada
Pfizer Investigational Site
London, Ontario, Canada
Pfizer Investigational Site
Oakville, Ontario, Canada
Pfizer Investigational Site
Toronto, Ontario, Canada
Pfizer Investigational Site
Toronto, Ontario, Canada
Pfizer Investigational Site
Toronto, Ontario, Canada
Pfizer Investigational Site
Montreal, Quebec, Canada
Pfizer Investigational Site
Montreal, Quebec, Canada
Pfizer Investigational Site
Pointe-Claire, Quebec, Canada
Pfizer Investigational Site
Aalborg, , Denmark
Pfizer Investigational Site
Herlev, , Denmark
Pfizer Investigational Site
Nykøbing Falster, , Denmark
Pfizer Investigational Site
Berlin, , Germany
Pfizer Investigational Site
Duisburg, , Germany
Pfizer Investigational Site
Frankfurt, , Germany
Pfizer Investigational Site
Muelheim A.d. Ruhr, , Germany
Pfizer Investigational Site
München, , Germany
Pfizer Investigational Site
München, , Germany
Pfizer Investigational Site
Rosenheim, , Germany
Pfizer Investigational Site
Starnberg, , Germany
Pfizer Investigational Site
Latina, , Italy
Pfizer Investigational Site
Padua, , Italy
Pfizer Investigational Site
Guadalajara, Jalisco, Mexico
Pfizer Investigational Site
Zapopan, Jalisco, Mexico
Pfizer Investigational Site
Tlalpan, México DF, Mexico
Pfizer Investigational Site
Durango, , Mexico
Pfizer Investigational Site
Durango, , Mexico
Pfizer Investigational Site
Bodø, , Norway
Pfizer Investigational Site
Moelv, , Norway
Pfizer Investigational Site
Bratislava, , Slovakia
Pfizer Investigational Site
Košice, , Slovakia
Pfizer Investigational Site
Malacky, , Slovakia
Pfizer Investigational Site
Martin, , Slovakia
Pfizer Investigational Site
Skalica, , Slovakia
Pfizer Investigational Site
Bloemfontein, Free State, South Africa
Pfizer Investigational Site
Bloemfontein, Free State, South Africa
Pfizer Investigational Site
Parktown, Gauteng, South Africa
Pfizer Investigational Site
Durban, KwaZulu-Natal, South Africa
Pfizer Investigational Site
Pietermaritzburg, KwaZulu-Natal, South Africa
Pfizer Investigational Site
Cape Town, , South Africa
Pfizer Investigational Site
Bucheon-si, Gyunggi-do, South Korea
Pfizer Investigational Site
Busan, , South Korea
Pfizer Investigational Site
Seoul, , South Korea
Pfizer Investigational Site
Seoul, , South Korea
Pfizer Investigational Site
A Coruña, A Coruña, Spain
Pfizer Investigational Site
Palma de Mallorca, Balearic Islands, Spain
Pfizer Investigational Site
Barcelona, , Spain
Pfizer Investigational Site
Granada, , Spain
Pfizer Investigational Site
Madrid, , Spain
Pfizer Investigational Site
Madrid, , Spain
Pfizer Investigational Site
Valencia, , Spain
Pfizer Investigational Site
Borås, , Sweden
Pfizer Investigational Site
Huskvarna, , Sweden
Pfizer Investigational Site
Lund, , Sweden
Pfizer Investigational Site
Skövde, , Sweden
Pfizer Investigational Site
Hualien City, , Taiwan
Pfizer Investigational Site
Kaohsiung City, , Taiwan
Pfizer Investigational Site
Taipei, , Taiwan
Pfizer Investigational Site
Taipei, , Taiwan
Pfizer Investigational Site
Adana, , Turkey (Türkiye)
Pfizer Investigational Site
Istanbul, , Turkey (Türkiye)
Pfizer Investigational Site
Izmir, , Turkey (Türkiye)
Pfizer Investigational Site
Sihhiye-Ankara, , Turkey (Türkiye)
Pfizer Investigational Site
Bristol, Avon, United Kingdom
Pfizer Investigational Site
Crewe, Cheshire, United Kingdom
Pfizer Investigational Site
Taunton, Somerset, United Kingdom
Pfizer Investigational Site
London, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Chapple C, Herschorn S, Abrams P, Sun F, Brodsky M, Guan Z. Tolterodine treatment improves storage symptoms suggestive of overactive bladder in men treated with alpha-blockers. Eur Urol. 2009 Sep;56(3):534-41. doi: 10.1016/j.eururo.2008.11.026. Epub 2008 Nov 24.
Related Links
Access external resources that provide additional context or updates about the study.
To obtain contact information for a study center near you, click here.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
A6121127
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.